Tags

Type your tag names separated by a space and hit enter

SSRIs do not worsen Parkinson's disease: evidence from an open-label, prospective study.
Clin Neuropharmacol. 2001 Jul-Aug; 24(4):221-7.CN

Abstract

Selective serotonin reuptake inhibitors (SSRIs) have been reported to be useful in the treatment of depression in patients with Parkinson's disease (PD). However, a few reports have suggested that SSRIs may worsen parkinsonian motor symptomatology and extrapyramidal side effects have been reported in depressed patients treated with SSRIs. So far, no prospective trial comparing the effects of different SSRIs in depressed patients with PD has been performed. The aim of the present study was to assess the effects of four SSRIs (citalopram, fluoxetine, fluvoxamine, and sertraline) on motor performance and their efficacy on depression in a group of patients with PD. Sixty-two consecutive nondemented, nonfluctuating, depressed patients with PD were included in four treatment groups (15 patiens received citalopram, 16 fluoxetine, 16 fluvoxamine, and 15 sertraline). The evaluation of extrapyramidal and depressive symptomatology was performed with use of the Unified Parkinson's Disease Rating Scale (UPDRS), Beck Depression Inventory, and Hamilton Depression Rating Scale at baseline and after 1, 3, and 6 months. Fifty-two patients completed the study. UPDRS scores were not significantly modified by the add-on therapy with each of the SSRIs studied. A significant improvement in depressive symptoms from baseline to the end of the trial was obtained with all SSRIs (Beck and Hamilton scores improving; p < 0.05 according to an analysis of variance). Our findings suggest that SSRIs do not significantly worsen extrapyramidal symptomatology and may ameliorate depression in patients with PD.

Authors+Show Affiliations

Department of Neuroscience, Clinical Neurology, and Department of Psychiatry, University of Pisa, Italy.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

11479393

Citation

Dell'Agnello, G, et al. "SSRIs Do Not Worsen Parkinson's Disease: Evidence From an Open-label, Prospective Study." Clinical Neuropharmacology, vol. 24, no. 4, 2001, pp. 221-7.
Dell'Agnello G, Ceravolo R, Nuti A, et al. SSRIs do not worsen Parkinson's disease: evidence from an open-label, prospective study. Clin Neuropharmacol. 2001;24(4):221-7.
Dell'Agnello, G., Ceravolo, R., Nuti, A., Bellini, G., Piccinni, A., D'Avino, C., Dell'Osso, L., & Bonuccelli, U. (2001). SSRIs do not worsen Parkinson's disease: evidence from an open-label, prospective study. Clinical Neuropharmacology, 24(4), 221-7.
Dell'Agnello G, et al. SSRIs Do Not Worsen Parkinson's Disease: Evidence From an Open-label, Prospective Study. Clin Neuropharmacol. 2001 Jul-Aug;24(4):221-7. PubMed PMID: 11479393.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - SSRIs do not worsen Parkinson's disease: evidence from an open-label, prospective study. AU - Dell'Agnello,G, AU - Ceravolo,R, AU - Nuti,A, AU - Bellini,G, AU - Piccinni,A, AU - D'Avino,C, AU - Dell'Osso,L, AU - Bonuccelli,U, PY - 2001/8/2/pubmed PY - 2002/1/5/medline PY - 2001/8/2/entrez SP - 221 EP - 7 JF - Clinical neuropharmacology JO - Clin Neuropharmacol VL - 24 IS - 4 N2 - Selective serotonin reuptake inhibitors (SSRIs) have been reported to be useful in the treatment of depression in patients with Parkinson's disease (PD). However, a few reports have suggested that SSRIs may worsen parkinsonian motor symptomatology and extrapyramidal side effects have been reported in depressed patients treated with SSRIs. So far, no prospective trial comparing the effects of different SSRIs in depressed patients with PD has been performed. The aim of the present study was to assess the effects of four SSRIs (citalopram, fluoxetine, fluvoxamine, and sertraline) on motor performance and their efficacy on depression in a group of patients with PD. Sixty-two consecutive nondemented, nonfluctuating, depressed patients with PD were included in four treatment groups (15 patiens received citalopram, 16 fluoxetine, 16 fluvoxamine, and 15 sertraline). The evaluation of extrapyramidal and depressive symptomatology was performed with use of the Unified Parkinson's Disease Rating Scale (UPDRS), Beck Depression Inventory, and Hamilton Depression Rating Scale at baseline and after 1, 3, and 6 months. Fifty-two patients completed the study. UPDRS scores were not significantly modified by the add-on therapy with each of the SSRIs studied. A significant improvement in depressive symptoms from baseline to the end of the trial was obtained with all SSRIs (Beck and Hamilton scores improving; p < 0.05 according to an analysis of variance). Our findings suggest that SSRIs do not significantly worsen extrapyramidal symptomatology and may ameliorate depression in patients with PD. SN - 0362-5664 UR - https://www.unboundmedicine.com/medline/citation/11479393/SSRIs_do_not_worsen_Parkinson's_disease:_evidence_from_an_open_label_prospective_study_ L2 - https://doi.org/10.1097/00002826-200107000-00005 DB - PRIME DP - Unbound Medicine ER -